Paul Hourd

The management of risk and investment in cell therapy process development: a case study for neurodegenerative disease.

David J. Williams, Amit Chandra, Sujith Sebastian, 2019, Regenerative medicine.

Application of response surface methodology to maximize the productivity of scalable automated human embryonic stem cell manufacture.

Elizabeth Ratcliffe, Paul Hourd, David J Williams, 2013, Regenerative medicine.

Feeling the pain: Disruptive Innovation in Healthcare Markets

David J. Williams, Amit Chandra, Paul Hourd, 2008, BASYS.

Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability.

Amit Chandra, Paul Hourd, David J Williams, 2014, Cytotherapy.

Qualification of academic facilities for small-scale automated manufacture of autologous cell-based products.

David J. Williams, Elizabeth Ratcliffe, Amit Chandra, 2014, Regenerative medicine.

Comparability: manufacturing, characterization and controls, report of a UK Regenerative Medicine Platform Pluripotent Stem Cell Platform Workshop, Trinity Hall, Cambridge, 14–15 September 2015

Anne L Plant, Ivan Wall, Glyn Stacey, 2016, Regenerative medicine.